ClinicalTrials.gg
Active, not recruitingNCT07163221At-home ULTRAUpdated Nov 18, 2026

At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]

An interventional study of Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1 and Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2 in Rheumatoid Arthritis (RA), sponsored by SecondWave Systems Inc.. Active, not recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by SecondWave Systems Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 121 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Planned enrollment
497th of 771
60 · median 120
Started
2025
with 30 others
No phase
164 of 975
18 open now
Primary completion
2026-10
later than 24 of 120 live
Registered
946th of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 497th largest by planned enrollment of the 771 interventional ones that give a count, is one of 31 that started in 2025, is one of 164 with no phase, reaches primary completion later than 24 of the 120 other live ones, and was the 946th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

The At-Home ULTRA Study will evaluate performance of the MINI system as indicated for the treatment of adults with active, moderate to severe rheumatoid arthritis who are inadequate responders or are intolerant to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs). The non-invasive study device delivers ultrasound stimulation to the spleen to reduce inflammation. The study will enroll at least 60 participants at up to 8 sites. There will be three arms consisting of two active stimulation groups (treatment) and one non-active stimulation group (sham-control). After completing the double-blinded primary endpoint assessment period at Week 12, there will be a one-way crossover of control participants to active stimulation and an additional 12 week follow-up with all participants to evaluate long-term outcomes.

03

Conditions studied

  • Rheumatoid Arthritis (RA)

Keywords

  • RA
  • SecondWave Systems
  • SecondWave
  • Rheumatoid Arthritis
  • Neuromodulation
  • Ultrasound
  • Splenic Ultrasound
  • Spleen
  • Spleen stimulation
  • Ultrasound Stimulation
  • Immunomodulation
  • spleen stimulating device
  • drug refractory
  • noninvasive
  • non-invasive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ages 18 and above
  2. Active moderate to severe seropositive RA
  3. At least 6 total tender and/or swollen joints counted on a 28 joint assessment during screening and at Week 0 (a joint that is both tender and swollen will be counted as "2")
  4. Demonstrated an inadequate response to, or loss of response to standard csDMARD treatment (e.g., methotrexate) or up to three total bDMARDs and tsDMARDs
  5. Receiving stable background treatment with a csDMARD prior to start of the treatment period at Week 0. Methotrexate (if chosen as background treatment) must be maintained at a stable dose for at least 4 weeks prior to Week 0, while all other csDMARDs (if chosen as background treatment) must be maintained at a stable dose for at least 8 weeks prior to Week 0. Participants must be willing to maintain their background medication regimen throughout the 28-week study period.
  6. For participants that have previously undergone treatment with bDMARDs or tsDMARDs therapy, those treatments must be discontinued at least 4 weeks prior to start of the treatment period at Week 0 and may not be resumed until after the Week 24 Closeout Visit
  7. For participants that have previously undergone treatment with Golimumab or Infliximab, those treatments must be discontinued at least 8 weeks prior to start of the treatment period at Week 0 and may not be resumed until after the Week 24 Closeout Visit
  8. Participants may receive up to 10 mg of daily prednisone as part of their background treatment but must have maintained a stable dose for a minimum of 6 weeks prior to start of the treatment period at Week 0, and must be willing to maintain the stable dose until after the Week 24 Closeout Visit
  9. Torso circumference at the belly button and sternum level must both be in the range of 25 to 50 inches
  10. Participants with an immunomodulation device must be willing and able to turn the device off at least 4 weeks prior to start of the treatment period at Week 0 and may not be resumed until after the Week 24 Closeout Visit
  11. Participants must be willing not to initiate any new treatments with expected immune modulating effects during the study period, and any existing immune modulating treatments must be stabilized by Week 0
  12. Participants must be willing and able to follow the medication rules described in the study's IRB-approved Medication Guide

Exclusion criteria

Exclusion Criteria:

  1. Active bacterial or viral infection
  2. Pregnant women or those trying to become pregnant
  3. Receiving active chemotherapy or immunotherapy to treat within 30 days prior to enrollment
  4. Having received more than a total of three bDMARDs and tsDMARDs
  5. Having received Rituximab monoclonal antibody medication
  6. Presence of an implanted device or other solid object in the vicinity of the spleen that can interfere with or absorb the ultrasound beam
  7. History of asplenia
  8. History of splenomegaly
  9. History of ascites
  10. Recent abdominal surgery
  11. Currently participating in an drug or device study
  12. Open wound/sores that would make performing study procedures too difficult
  13. Inability to perform minimal daily self-cares associated with feeding or dressing, such as lifting a cup of water to the mouth or putting on clothing.
  14. Refusal or inability to regularly attend the scheduled on-site visits and at-home visits, or perform the remote video observation sessions
  15. Cannot speak English
  16. Any other clinical reasons deemed by the investigators of the study in which the patient would not be an appropriate candidate for the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Sham comparator
    Control

    Non-active Sham Stimulation

    Device: Sham ultrasound stimulation (control) · Drug: Conventional Synthetic DMARD

  • Experimental
    Treatment Setting 1

    Subjects will receive daily noninvasive ultrasound stimulation of the spleen using Ultrasound Treatment Setting 1 for 20 minutes once per day

    Device: Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1 · Drug: Conventional Synthetic DMARD

  • Experimental
    Treatment Setting 2

    Subjects will receive daily noninvasive ultrasound stimulation of the spleen using Ultrasound Treatment Setting 2 for 20 minutes once per day

    Device: Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2 · Drug: Conventional Synthetic DMARD

Interventions

  • DeviceNon-invasive ultrasound stimulation of the spleen - Treatment Setting 1

    Subjects will receive daily noninvasive ultrasound stimulation of the spleen using Ultrasound Treatment Setting 1 for 20 minutes once per day

  • DeviceNon-invasive ultrasound stimulation of the spleen - Treatment Setting 2

    Subjects will receive daily noninvasive ultrasound stimulation of the spleen using Ultrasound Treatment Setting 2 for 20 minutes once per day

  • DeviceSham ultrasound stimulation (control)

    Sham ultrasound stimulation for 20 minutes once per day

  • DrugConventional Synthetic DMARD

    All subjects will take at least one type of conventional synthetic DMARD at the same stable dose for at least 8 weeks prior to the treatment period and continuing through study close out

06

What researchers measure

Primary outcomes

  1. Change in DAS28-CRP score from baseline to 12 weeks, compared between Arm 1 and Arm 3 (sham control)

    A decrease in Disease Activity Score indicates an improved outcome

    Time frame: 12 weeks

  2. Change in DAS28-CRP score from baseline to 12 weeks , compared between Arm 2 and Arm 3 (sham control)

    A decrease in Disease Activity Score indicates an improved outcome

    Time frame: 12 weeks

Other outcomes

  1. Comparison of responder rate between Arm1 or Arm 2 versus Arm 3 for the ACR20

    ACR20, the American College of Rheumatology (ACR) 20 response is defined as 20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and an acute-phase reactant

    Time frame: 12 and 24 weeks

  2. Comparison of responder rate between Arm1 or Arm 2 versus Arm 3 for the ACR50

    ACR50, the American College of Rheumatology (ACR) 50 response is defined as 50% improvement in tender and swollen joint counts and 50% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and an acute-phase reactant

    Time frame: 12 and 24 weeks

  3. Comparison of responder rate between Arm1 or Arm 2 versus Arm 3 for the ACR70

    ACR70, the American College of Rheumatology (ACR) 70 response is defined as 70% improvement in tender and swollen joint counts and 70% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and an acute-phase reactant

    Time frame: 12 and 24 weeks

  4. Good EULAR response

    European Alliance of Associations for Rheumatology (EULAR) "good" response corresponding to clinical improvement in patients with rheumatoid arthritis (RA) and is defined by a DAS28-CRP of ≤3.2 and a DAS28-CRP decrease of more than 1.2 from the baseline score

    Time frame: 12 and 24 weeks

  5. Moderate EULAR response

    European Alliance of Associations for Rheumatology (EULAR) "moderate" response corresponding to clinical improvement in rheumatoid arthritis (RA) and is defined as either a decrease in DAS28-CRP of \>0.6 to ≤1.2 while maintaining a DAS28 score of ≤5.1, OR a decrease of \>1.2 in DAS28-CRP but with a current score \>3.2

    Time frame: 12 and 24 weeks

  6. Satisfaction response

    Questions to assess benefit, acceptance and usability of the treatment

    Time frame: 12 and 24 weeks

  7. Change in HAQ-DI

    The Health Assessment Questionnaire Disability Index (HAQ-DI) is made up of 8 domains of daily activity. A decrease in score indicates improved physical function

    Time frame: 12 and 24 weeks

  8. Change in DAS28-CRP score from baseline to 24 weeks, compared between Arm 1 and Arm 3 (sham control)

    A decrease in Disease Activity Score indicates an improved outcome

    Time frame: 24 weeks

  9. Change in DAS28-CRP score from baseline to 24 weeks, compared between Arm 2 and Arm 3 (sham control)

    A decrease in Disease Activity Score indicates an improved outcome

    Time frame: 24 weeks

07

Study locations

5 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Oct 2026, 11 months.

Of 56 industry-sponsored interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 92. This study's 11 months is below that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2025
First posted
Sep 9, 2025
StartActual
Nov 3, 2025
Primary completionActual
Oct 6, 2026
CompletionEst.
Jan 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07163221
Lead sponsor
SecondWave Systems Inc.
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
Nov 3, 2025
Primary completion
Oct 6, 2026
Completion
Jan 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Daniel Zachs
study director · SecondWave Systems Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion